United upswing

Despite receiving two complete response letters from FDA for pulmonary arterial hypertension drug treprostinil in the past six months, United Therapeutics Inc. (NASDAQ:UTHR) shares continue to climb, due in part to the company's bulging coffers and history of share buybacks.